Mentor executes long-term funding agreement to receive 50% ownership in Brighter Day Health

Mentor Capital, Inc. (OTC Markets: MNTR) announced that it has executed a long-term funding agreement to receive a current 50% ownership in Brighter Day Health, LLC, pending their expected shareholder approval. Brighter Day provides face-to-face doctor interaction through secure computer video set-ups for ultra-economic health care delivery at nursing homes and similar treatment facilities. Mentor Capital is to provide $5.0 Million in future growth funding for Brighter Day Health to continue its multi-state expansion plan.

"Reducing the cost and inconvenience of the routine or follow-up doctor visit for often challenged cancer or other patients is an obvious plus for all parties involved with a compromised patient," says Mentor Capital CEO, Chester Billingsley. Edward Mashek, the CEO of Brighter Day Health, explains, "Telemedicine is the fastest growing method of delivering face-to-face healthcare to patients in the United States. Brighter Day Health has been an early leader in this field and is partnering with Mentor Capital to finance our accelerated facility and video system additions."

The Brighter Day Health portfolio addition brings Mentor Capital cancer and financial assets to $10 Million from $1.0 Million in November 2011. Mentor has approximately 2.9 Million basic shares outstanding and has traded in the quarterly range of $0.10 to $0.26 per share.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Innovative urine test could improve pancreatic cancer survival rates